SciSparc Ltd. announced that the process of granting and validation for its core-technology patent has been completed in certain European countries. This patent covers combinations of cannabinoids and n-acylethanolamines. The Patent aligns seamlessly with the Company's proprietary technology designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.

The Patent was granted and validated in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein and the United Kingdom. This grant adds to the patent portfolio of the Company, thereby supporting the innovation of SciSparc's technologies. The invention relates to compositions and methods for potentiating therapeutic effects and/or reducing the side- effects of selected cannabinoids initially discovered in the cannabis plant.

The Patent approval was granted on account of the unique composition of cannabinoids and n-acylthanolamines and the methods for their use in preventing and treating a variety of cannabinoid-treated conditions.